Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Comment by Goldisgreaton Sep 29, 2017 11:10am
89 Views
Post# 26758635

RE:RE:RE:I Found This Interesting...

RE:RE:RE:I Found This Interesting...Brossard, Quebec, Canada – September 19th, 2017 - DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK, OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today a development of new cardiovascular risk score, that will enable the early detection of this critical disease by its CARA platform. The calibration of our application will be done simultaneously in 4 countries with a minimum of 1,000 in each country with the support of 22 cardiologists. This will enable us to insure the sustainability of our solution worldwide. The partners that will be collaborating with DIAGNOS are in Algeria, Canada, Mexico and United States. “We’re at the final development stage and ready to evaluate the effectiveness of our automatic grading for the new risk score test CARA Cardio. Continually, we hear from physicians and health insurers that our screening tests are very much needed to detect at early stage the cardiovascular anomalies. Our preventive cardiovascular risk score test will be used to prospectively predict and monitor the cardiovascular artery diseases. Diagnos’ AI will automatically grade the retinal microcirculation state to generate this score. At regular interval, we will monitor the patients using the same test” said Dr Hadi Chakor, Diagnos Chief Medical Officer. “Our test will precede painful and stressing invasive procedure that may cause costly late complication.”
Bullboard Posts